Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05754424Phase 1Completed

AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study

Role: lead

NCT05184868Phase 1Completed

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

Role: lead

NCT04660305Phase 1Completed

AT278 and NovoRapid® in Glucose Clamp Study

Role: lead

NCT03959514Phase 1Completed

AT247, NovoRapid® and Fiasp® in Glucose Clamp Study

Role: lead

All 4 trials loaded